

Special Issue

Opportunities and Challenges in Multiple Myeloma Treatment and Management

Message from the Guest Editors

Multiple myeloma (MM) is a hematological malignancy characterized by a high propensity for recurrence and drug resistance. A wide range of genetic and epigenetic abnormalities have been implicated in the pathogenesis of this cancer, ultimately affecting the growth, survival and drug sensitivity of multiple myeloma cells. Although many therapeutic agents have been developed to improve the depth and duration of response and prolong patient survival, the management of multiple myeloma remains challenging due to the eventual emergence of drug-resistant clones and often imminent relapse. These events have prompted continued research to identify new molecular lesions and therapeutic targets, with the ultimate goal of finding a cure for multiple myeloma. Therefore, this special issue focuses on the tumor microenvironment and mechanisms of deterioration, i.e. drug resistance, proliferative signaling, immune evasion, etc., which are involved in the aggressive disease behavior of refractory MM, to better manage those that develop into new treatment strategy.

Click [here](#) to submit

Guest Editors

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

Dr. Giovanni Martinelli

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, FC, Italy

Deadline for manuscript submissions

closed (30 May 2023)



Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



mdpi.com/si/137938

Hematology Reports
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
hematolrep@mdpi.com

[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)





Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)



About the Journal

Message from the Editor-in-Chief

Hematology Reports (ISSN 2038-8330) is an international open access journal on all aspects of prevention, diagnosis and management of disorders of the blood, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology and controlled trials.

Editor-in-Chief

Dr. Claudio Cerchione
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014
Meldola, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 29.4 days after submission; acceptance to publication is undertaken in 4.6 days (median values for papers published in this journal in the second half of 2025).